Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019

David K. Lau; Matthew Burge; Amitesh Roy; Ian Chau; Daniel G. Haller; Jeremy D. Shapiro; Marc Peeters; Nick Pavlakis; Christos S. Karapetis; Niall C. Tebbutt; Eva Segelov; Timothy J. Price

doi:10.1080/14737140.2020.1744439

Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019

David K. Lau, Matthew Burge, Amitesh Roy, Ian Chau, Daniel G. Haller, Jeremy D. Shapiro, Marc Peeters, Nick Pavlakis, Christos S. Karapetis, Niall C. Tebbutt, Eva Segelov, Timothy J. Price

Research output: Contribution to journal › Review article › peer-review

5 Citations (Scopus)

Abstract

Introduction: Outcomes in metastatic colorectal cancer are improving, due to the tailoring of therapy enabled by better understanding of clinical behavior according to molecular subtype.

Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This review summarizes expert discussion of the current evidence for therapies in metastatic colorectal cancer (mCRC) based on molecular subgrouping.

Expert opinion: EGFR-targeted and VEGF-targeted antibodies are now routinely incorporated into treatment strategies for mCRC. EGFR-targeted antibodies are restricted to patients with extended RAS wild-type profiles, with evidence that they should be further restricted to patients with left-sided tumors. Clinically distinct treatment pathways based on tumor RAS, BRAF, HER2 and MMR status, are now clinically applicable. Evidence suggests therapy for additional subgroups will soon be defined; the most advanced being for patients with KRAS G12 C mutation and gene TRK fusion defects.

Original language	English
Pages (from-to)	251-270
Number of pages	20
Journal	Expert Review of Anticancer Therapy
Volume	20
Issue number	4
DOIs	https://doi.org/10.1080/14737140.2020.1744439
Publication status	Published - 6 Apr 2020

Keywords

BRAF
chemotherapy
Colorectal
consensus
metastatic
MSI
RAS

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/14737140.2020.1744439Licence: In Copyright

Cite this

Lau, D. K., Burge, M., Roy, A., Chau, I., Haller, D. G., Shapiro, J. D., Peeters, M., Pavlakis, N., Karapetis, C. S., Tebbutt, N. C., Segelov, E., & Price, T. J. (2020). Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. Expert Review of Anticancer Therapy, 20(4), 251-270. https://doi.org/10.1080/14737140.2020.1744439

@article{54eca10efa8343e48670b2570a739d18,

title = "Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019",

abstract = "Introduction: Outcomes in metastatic colorectal cancer are improving, due to the tailoring of therapy enabled by better understanding of clinical behavior according to molecular subtype.Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This review summarizes expert discussion of the current evidence for therapies in metastatic colorectal cancer (mCRC) based on molecular subgrouping.Expert opinion: EGFR-targeted and VEGF-targeted antibodies are now routinely incorporated into treatment strategies for mCRC. EGFR-targeted antibodies are restricted to patients with extended RAS wild-type profiles, with evidence that they should be further restricted to patients with left-sided tumors. Clinically distinct treatment pathways based on tumor RAS, BRAF, HER2 and MMR status, are now clinically applicable. Evidence suggests therapy for additional subgroups will soon be defined; the most advanced being for patients with KRAS G12 C mutation and gene TRK fusion defects.",

keywords = "BRAF, chemotherapy, Colorectal, consensus, metastatic, MSI, RAS",

author = "Lau, {David K.} and Matthew Burge and Amitesh Roy and Ian Chau and Haller, {Daniel G.} and Shapiro, {Jeremy D.} and Marc Peeters and Nick Pavlakis and Karapetis, {Christos S.} and Tebbutt, {Niall C.} and Eva Segelov and Price, {Timothy J.}",

year = "2020",

month = apr,

day = "6",

doi = "10.1080/14737140.2020.1744439",

language = "English",

volume = "20",

pages = "251--270",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Taylor & Francis",

number = "4",

}

TY - JOUR

T1 - Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting

T2 - ESMO congress 2019

AU - Lau, David K.

AU - Burge, Matthew

AU - Roy, Amitesh

AU - Chau, Ian

AU - Haller, Daniel G.

AU - Shapiro, Jeremy D.

AU - Peeters, Marc

AU - Pavlakis, Nick

AU - Karapetis, Christos S.

AU - Tebbutt, Niall C.

AU - Segelov, Eva

AU - Price, Timothy J.

PY - 2020/4/6

Y1 - 2020/4/6

N2 - Introduction: Outcomes in metastatic colorectal cancer are improving, due to the tailoring of therapy enabled by better understanding of clinical behavior according to molecular subtype.Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This review summarizes expert discussion of the current evidence for therapies in metastatic colorectal cancer (mCRC) based on molecular subgrouping.Expert opinion: EGFR-targeted and VEGF-targeted antibodies are now routinely incorporated into treatment strategies for mCRC. EGFR-targeted antibodies are restricted to patients with extended RAS wild-type profiles, with evidence that they should be further restricted to patients with left-sided tumors. Clinically distinct treatment pathways based on tumor RAS, BRAF, HER2 and MMR status, are now clinically applicable. Evidence suggests therapy for additional subgroups will soon be defined; the most advanced being for patients with KRAS G12 C mutation and gene TRK fusion defects.

AB - Introduction: Outcomes in metastatic colorectal cancer are improving, due to the tailoring of therapy enabled by better understanding of clinical behavior according to molecular subtype.Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This review summarizes expert discussion of the current evidence for therapies in metastatic colorectal cancer (mCRC) based on molecular subgrouping.Expert opinion: EGFR-targeted and VEGF-targeted antibodies are now routinely incorporated into treatment strategies for mCRC. EGFR-targeted antibodies are restricted to patients with extended RAS wild-type profiles, with evidence that they should be further restricted to patients with left-sided tumors. Clinically distinct treatment pathways based on tumor RAS, BRAF, HER2 and MMR status, are now clinically applicable. Evidence suggests therapy for additional subgroups will soon be defined; the most advanced being for patients with KRAS G12 C mutation and gene TRK fusion defects.

KW - BRAF

KW - chemotherapy

KW - Colorectal

KW - consensus

KW - metastatic

KW - MSI

KW - RAS

UR - http://www.scopus.com/inward/record.url?scp=85082969958&partnerID=8YFLogxK

U2 - 10.1080/14737140.2020.1744439

DO - 10.1080/14737140.2020.1744439

M3 - Review article

C2 - 32186929

AN - SCOPUS:85082969958

SN - 1473-7140

VL - 20

SP - 251

EP - 270

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

IS - 4

ER -

Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this